Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Frontiers in Immunology|May 25, 2026
Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature reviewNa Hu, Ziyue Wang, Ming Liu, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 16, 2025
Integration of Circulating Tumor DNA and Metabolic Parameters on 18F-Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non-Small Cell Lung CancerLeilei Wu, Zhenshan Zhang, Chenxue Jiang, et al.Experimental Hematology & Oncology|March 15, 2024
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasisLiang Liu, Xiaodong Chen, Leilei Wu, et al.ACS Medicinal Chemistry Letters|September 16, 2014
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein InteractionZhisen Zhang, Zhaohu Lin, Zheng Zhou, et al.Bioorganic & Medicinal Chemistry Letters|March 31, 2009
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonistSong Feng, Minmin Yang, Zhenshan Zhang, et al.Journal of Medicinal Chemistry|September 20, 2014
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitorsGuozhi Tang, Jason C Wong, Weixing Zhang, et al.Journal of Medicinal Chemistry|March 4, 2015
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitorsXianfeng Lin, Wenming Chen, Zongxing Qiu, et al.Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapyJason C Wong, Lei Guo, Zhenghong Peng, et al.Vaccine|November 5, 2005
Preparation and characterization of SARS in-house reference antiserumJiansan Zhang, Yuxuan Liu, Liangxiang Hu, et al.Lancet (London, England)|September 19, 2006
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialJiangtao Lin, Jiansan Zhang, Xiaoping Dong, et al.Pageof 6